MilliporeSigma
  • Home
  • Search Results
  • Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

Cell metabolism (2014-10-09)
Sarah M Turpin, Hayley T Nicholls, Diana M Willmes, Arnaud Mourier, Susanne Brodesser, Claudia M Wunderlich, Jan Mauer, Elaine Xu, Philipp Hammerschmidt, Hella S Brönneke, Aleksandra Trifunovic, Giuseppe LoSasso, F Thomas Wunderlich, Jan-Wilhelm Kornfeld, Matthias Blüher, Martin Krönke, Jens C Brüning
ABSTRACT

Ceramides increase during obesity and promote insulin resistance. Ceramides vary in acyl-chain lengths from C14:0 to C30:0 and are synthesized by six ceramide synthase enzymes (CerS1-6). It remains unresolved whether obesity-associated alterations of specific CerSs and their defined acyl-chain length ceramides contribute to the manifestation of metabolic diseases. Here we reveal that CERS6 mRNA expression and C16:0 ceramides are elevated in adipose tissue of obese humans, and increased CERS6 expression correlates with insulin resistance. Conversely, CerS6-deficient (CerS6(Δ/Δ)) mice exhibit reduced C16:0 ceramides and are protected from high-fat-diet-induced obesity and glucose intolerance. CerS6 deletion increases energy expenditure and improves glucose tolerance, not only in CerS6(Δ/Δ) mice, but also in brown adipose tissue- (CerS6(ΔBAT)) and liver-specific (CerS6(ΔLIVER)) CerS6 knockout mice. CerS6 deficiency increases lipid utilization in BAT and liver. These experiments highlight CerS6 inhibition as a specific approach for the treatment of obesity and type 2 diabetes mellitus, circumventing the side effects of global ceramide synthesis inhibition.